El ensayo OASIS 1, en personas con obesidad y sobrepeso sin DM2, evidenci que la SEMA oral a 50 mg logr una prdida media del 15,1% del peso corporal frente al 2,4% con placebo en 68 semanas, aunque con una incidencia relevante de efectos gastrointestinales y disestesias en el 13% de participantes, lo que ha impulsado el estudio de dosis intermedias para optimizar eficacia y tolerabilidad
Curr Neurol Neurosci Rep 25 , 36 (2025)
Is the claimed use authorised in the UK
Always keep the prefilled syringes in the original carton to protect from light
Sandy, 52 Vyora Member Texas Arianne, 47 Vyora Member Washington Alyssa, 32 Vyora Member Vermont Amanda, 34 Vyora Member New Mexico Honest feedback from people experiencing the difference for themselves
Fatty acid side chain: A C-18 diacid chain is attached to the C-terminus, extending the half-life to approximately 7 days and enabling once-weekly dosing